BioMarin Shares Climb After Securing Royalty Deal in Ascendis Patent Settlement

Shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) climbed 5% after the company announced a global settlement with Ascendis Pharma A/S, resolving a series of patent disputes over Ascendis's drug, Yuviwel.

Terms of the Agreement

Under the settlement, Ascendis will pay BioMarin significant royalties on the net sales of Yuviwel. The agreement establishes a framework that recognizes BioMarin's intellectual property while ensuring patient access to treatments for achondroplasia, a form of dwarfism.

Key financial terms of the deal include:

• A 20% royalty on net sales of Yuviwel in the United States, retroactive to the first commercial sale.
• An 18% royalty on net sales in the European Union, Brazil, and South Korea.
• These royalty payments will continue until May 2030.

As part of the resolution, BioMarin has granted Ascendis a license for its patents related to Yuviwel. This license covers all current and potential indications, such as achondroplasia and hypochondroplasia, as well as the drug's use in combination with other medicines.

Resolution of Legal Disputes

Ad

The comprehensive settlement puts an end to all outstanding litigation between the two companies. BioMarin will dismiss its pending Section 337 investigation before the U.S. International Trade Commission.

Additionally, all related lawsuits pending in the Northern District of California, Brazil, Denmark, Germany, and South Korea will be resolved. This removes significant legal uncertainty and associated costs for both firms, a development positively received by investors.

Context and Market Impact

The dispute centered on BioMarin's innovations in C-type natriuretic peptide (CNP) technology, which is the basis for its own approved treatment, VOXZOGO (vosoritide). The settlement validates the strength of BioMarin's patent portfolio and establishes a new, high-margin revenue stream for the company from a competing product.

For investors, the deal is seen as a clear financial win for BioMarin, turning a legal adversary into a source of royalty income and reinforcing the value of its research and development in rare diseases.